Halozyme (HALO) Price & Analysis

Compare

990 Followers

HALO Stock Chart & Stats

Day’s Range― - ―

52-Week Range$41.28 - $66.00

Previous CloseN/A

Volume1.23M

Average Volume (3M)1.50M

Market Cap

$7.34B

Enterprise Value$7.11B

Total Cash (Recent Filing)$55.18M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)17.3

Beta0.91

Next Earnings

Aug 12, 2025

EPS Estimate

1.21

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)1.11

Shares Outstanding123,533,310

10 Day Avg. Volume1,166,115

30 Day Avg. Volume1,500,557

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)0.00

Price to Cash Flow (P/CF)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.97

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda10.99

Forecast

1Y Price Target

$68.44

Price Target Upside-2.42% Downside

Rating ConsensusModerate Buy

Number of Analyst Covering9

---

Halozyme News

---

Bulls Say, Bears Say

Bulls Say

Financial GuidanceHalozyme management increased financial guidance for 2025, projecting a revenue boost of $50 million and a rise in non-GAAP earnings by $0.35 per share.

Financial PerformanceHalozyme Technologies reported better-than-expected financial results, with revenues increasing by 35% and non-GAAP earnings rising from $0.79 to $1.11 per share.

Shareholder ReturnsThe company announced a new $250 million share repurchase program, indicating confidence in its financial position.

Bears Say

Intellectual Property UncertaintyManagement is confident in their claim that Merck is infringing on Halozyme's key intellectual property, but the outcome remains uncertain.

Litigation RiskHalozyme recently filed a patent infringement lawsuit against Merck, which presents an ongoing litigation risk.

Market CompetitionDespite strong positioning, Halozyme's ongoing litigation with Merck underscores the competitive pressure and potential challenges in protecting its technology.

---

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

1.09% Insiders

30.25% Mutual Funds

1.95% Other Institutional Investors

35.82% Public Companies and

Individual Investors

Detailed Ownership Overview >

HALO FAQ

What was Halozyme Therapeutics’s price range in the past 12 months?

Halozyme Therapeutics lowest stock price was $41.28 and its highest was $66.00 in the past 12 months.

What is Halozyme Therapeutics’s market cap?

Halozyme Therapeutics’s market cap is $7.34B.

When is Halozyme Therapeutics’s upcoming earnings report date?

Halozyme Therapeutics’s upcoming earnings report date is Aug 12, 2025 which is in 95 days.

How were Halozyme Therapeutics’s earnings last quarter?

Halozyme Therapeutics released its earnings results on May 06, 2025. The company reported $1.11 earnings per share for the quarter, beating the consensus estimate of $0.924 by $0.186.

Is Halozyme Therapeutics overvalued?

According to Wall Street analysts Halozyme Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Halozyme Therapeutics pay dividends?

Halozyme Therapeutics does not currently pay dividends.

What is Halozyme Therapeutics’s EPS estimate?

Halozyme Therapeutics’s EPS estimate is 1.21.

How many shares outstanding does Halozyme Therapeutics have?

Halozyme Therapeutics has 123,533,310 shares outstanding.

What happened to Halozyme Therapeutics’s price movement after its last earnings report?

Halozyme Therapeutics reported an EPS of $1.11 in its last earnings report, beating expectations of $0.924. Following the earnings report the stock price went up 18.121%.

Which hedge fund is a major shareholder of Halozyme Therapeutics?

Currently, no hedge funds are holding shares in HALO

---

Halozyme Stock Smart Score

Outperform

Fundamentals

Return on Equity

147.06%

Trailing 12-Months

Asset Growth

24.84%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Halozyme Therapeutics

Halozyme Therapeutics, Inc. (HALO) is a biotechnology company that focuses on developing and commercializing products that target the extracellular matrix for the enhancement of the delivery of drugs and the treatment of tumors. The company operates primarily in the healthcare sector and is known for its proprietary enzyme technology, including the ENHANZE drug delivery platform, which is designed to facilitate the subcutaneous delivery of biologics, potentially improving patient experience and outcomes.

---

HALO Company Deck

---

HALO Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call presented a strong financial performance with significant growth in revenue and profits driven by key blockbuster products. The company announced new growth catalysts and an increased guidance for 2025. However, ongoing litigation with Merck poses a potential risk, though it is not expected to impact the core business. Overall, the highlights significantly outweigh the lowlights.Read More>

---

HALO Revenue Breakdown

54.01% Royalties

36.28% Product sales

9.71% Revenues under collaborative agreements

---

HALO Stock 12 Month Forecast

Average Price Target

$68.44

▼(-2.42% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"38":"$38","59":"$59","80":"$80","48.5":"$48.5","69.5":"$69.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":79,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$79.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":68.44,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$68.44</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":53,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$53.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[38,48.5,59,69.5,80],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,60.03,61.48923076923077,62.94846153846154,64.40769230769232,65.86692307692307,67.32615384615384,68.78538461538461,70.24461538461539,71.70384615384616,73.16307692307693,74.62230769230769,76.08153846153846,77.54076923076923,{"y":79,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,60.03,60.676923076923075,61.323846153846155,61.97076923076923,62.61769230769231,63.26461538461538,63.91153846153846,64.55846153846154,65.20538461538462,65.85230769230769,66.49923076923076,67.14615384615385,67.79307692307692,{"y":68.44,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,60.03,59.48923076923077,58.94846153846154,58.40769230769231,57.86692307692308,57.326153846153844,56.785384615384615,56.244615384615386,55.70384615384616,55.16307692307692,54.62230769230769,54.08153846153846,53.54076923076923,{"y":53,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":39.3,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.29,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.02,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.05,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.85,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.64,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.15,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.59,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.81,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.64,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.15,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.87,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.03,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >